Gastric ulcer healing and stress-lesion preventive properties of pioglitazone are attenuated in diabetic rats

• Autorzy: Konturek P. C. , Brzozowski T. , Burnat G. , Szlachcic A. , Koziel J. , Kwiecien S. , Konturek S.J. , Harsch I.A.
• Języki publikacji: EN

Abstrakty

EN

Diabetes mellitus increases susceptibility to acute gastric injury and impairs ulcer healing. Pioglitazone as an agonist of peroxisome proliferator-activated receptor gamma (PPAR) is used as anti-diabetic drug and has additionally gastroprotective activities. However, the effect of pioglitazone on the protection and healing of gastric mucosa under diabetic conditions is poorly understood. The aim of the present study was: 1) to compare the effects of treatment with PPAR ligand (pioglitazone) on healing of acetic acid-induced gastric ulcers and prevention of acute water immersion and restraint stress (WRS)-induced gastric lesions in normal rats and those with streptozotocin (STZ)-induced diabetes mellitus; 2) to assess the effects of pioglitazone on the mRNA expression of cyclooxygenase-2 (COX-2), c-NOS, interleukin-1ß and hypoxia inducible factor-1 alpha (HIF-1) in the gastric mucosa of rats with or without STZ-induced diabetes mellitus; 3) to investigate the involvement of endogenous NO and proinflammatory cytokines (IL-1ß, TNF-) in healing of chronic gastric ulcers and in prevention of acute stress lesions by pioglitazone in rats with or without STZ-induced diabetes mellitus. Diabetes was induced in rats by single injection of STZ (70 mg/kg i.p.) four weeks prior to production of gastric ulcers by acetic acid method or induction of stress lesions by 3.5 hours of WRS. Non-diabetic rats were used as controls. Two major animal groups (A and B) were tested; A) diabetic and non-diabetic rats with chronic gastric ulcers treated with 1) pioglitazone (40 mg/kg-d i.g.), 2) pioglitazone in combination of blocker of NO synthase (L-NNA 20 mg/kg-d i.p.), and 3) saline (vehicle-control); and B) diabetic and non-diabetic rats exposed to 3.5 hours of WRS and pretreated with 1) pioglitazone (40 mg/kg i.g.), 2) pioglitazone in combination of blocker of NO synthase (L-NNA 20 mg/kg i.p.), and 3) saline (vehicle-control). The gastric mucosal blood flow was assessed by H2-gas clearance method. The area of chronic acetic acid ulcers and number of acute WRS-induced gastric lesions were assessed by planimetry or by counting of number of lesions, respectively. In rats with chronic ulcers, the mRNA expression of HIF-1, IL-1ß and COX-2 was assessed by RT-PCR and protein expression of platelet endothelial cell adhesion molecule-1 (PECAM-1), COX-2 and cNOS was examined by Western blot. In rats with stress lesions, the protein expression of COX-2, cNOS, catalase, PPAR and heat shock protein 70 (HSP70) was examined by Western blot. In diabetic rats, a marked delay in ulcer healing and increased susceptibility to WRS lesions were observed and these effects were accompanied by a significant decrease in GBF. Pioglitazone significantly increased healing of chronic gastric ulcers and exerted a strong protective effect against WRS-induced lesions, but these effects were attenuated by NO-inhibition with L-NNA. Interestingly, the ulcer healing and gastroprotective effects of pioglitazone were weak under diabetic conditions, and this effect on ulcer healing was accompanied by impaired angiogenesis due to decreased PECAM-1 expression, attenuated expression of COX-2 and the increased expression of proinflammatory cytokines compared to those in diabetic rats treated with vehicle. We conclude that: 1) experimental diabetes in rats impairs healing of chronic ulcers and enhances acute stress lesions due to an increase in the expression and release of proinflammatory cytokines such as TNF- and IL-1ß; 2) the ulcer healing effect of pioglitazone, which is, at least in part, mediated by endogenous NO, is significantly attenuated by L-NNA in diabetic rats despite increased COX-2 expression at the ulcer edge; 3) the formation of acute gastric lesions induced by WRS is also attenuated by pretreatment with pioglitazone due to increased GBF probably mediated by NO, as the administration of L-NNA reversed, in part, the preventive action induced by this PPAR ligand, and 4) pioglitazone is effective both in healing of chronic ulcers and protection against WRS lesions though its action under diabetic conditions seems to be attenuated, possibly due to reduction in NOS-NO system, angiogenesis and increased expression and release of proinflammatory cytokines.

Słowa kluczowe

EN

gastric ulcer; ulcer healing; healing; stress; diabetes mellitus; gastric injury; hypoxia inducible factor-1alpha; peroxisome proliferator-activated receptor gamma; cyclooxygenase-2; nitric oxide; cytokine; rat

• Wydawca: -
• Czasopismo: Journal of Physiology and Pharmacology
• Rocznik: 2010
• Tom: 61
• Numer: 4
• Opis fizyczny: p.429-436,fig.,ref.

Twórcy

autor

Konturek P. C.

• Thuringia Clinic Saalfeld, Rainweg 61, 07318 Saalfeld, Germany

autor

Brzozowski T.

autor

Burnat G.

autor

Szlachcic A.

autor

Koziel J.

autor

Kwiecien S.

autor

Konturek S.J.

autor

Harsch I.A.

Bibliografia

• Campbell RK. Type 2 diabetes: where we are today: an overview of disease burden, current treatments, and treatment strategies. J Am Pharm Assoc (2003) 2009; 49(Suppl 1): S3-S9.
• Harsch IA, Brzozowski T, Bazela K, et al. Impaired gastric ulcer healing in diabetic rats: role of heat shock protein, growth factors, prostaglandins and proinflammatory cytokines. Eur J Pharmacol 2003; 481: 249-260.
• Korolkiewicz R, Tashima K, Kubomi M, Kato S, Takeuchi K. Increased susceptibility of diabetic rat gastric mucosa to food deprivation during cold stress. Digestion 1999; 60: 528-537.
• Tashima K, Fujita A, Takeuchi K. Aggravation of ischemia/reperfusion-induced gastric lesions in streptozotocin-diabetic rats. Life Sci 2000; 67: 1707-1718.
• Brzozowska I, Targosz A, Sliwowski Z, et al. Healing of chronic gastric ulcers in diabetic rats treated with native aspirin, nitric oxide (NO)-derivative of aspirin and cyclooxygenase (COX)-2 inhibitor. J Physiol Pharmacol 2004; 55: 773-790.
• Takeuchi K, Takehara K, Tajima K, Kato S, Hirata T. Impaired healing of gastric lesions in streptozotocin-induced diabetic rats: impaired effect of basic fibroblast growth factor. J Pharmacol Exp Ther 1997; 281: 200-207.
• Boden G, Zhang M. Recent findings concerning thiazolidinediones in the treatment of diabetes. Expert Opin Investig Drugs 2006; 15: 243-250.
• Clar C, Royle P, Waugh N. Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis. PLoS One 2009; 4: e6112.
• Bodmer M, Meier C, Kraenzlin ME, Meier CR. Risk of fractures with glitazones: a critical review of the evidence to date. Drug Saf 2009; 32: 539-547.
• Patel RR. Thiazolidinediones and congestive heart failure: a judicious balance of risks and benefits. Cardiol Rev 2009; 17: 132-135.
• Brzozowski T Konturek PC, Pajdo R, et al. Agonist of peroxisome proliferator-activated receptor gamma (PPAR-g): a new compound with potent gastroprotective and ulcer healing properties. Inflammopharmacology 2005; 13: 317-330.
• Wada K, Nakajima A, Takahashi H, et al. Protective effect of endogenous PPARamma against acute gastric mucosal lesions associated with ischemia-reperfusion. Am J Physiol Gastrointest Liver Physiol 2004; 287: G452-G458.
• Konturek PC, Brzozowski T, Kania J, et al. Pioglitazone, a specific ligand of peroxisome proliferator-activated receptor-gamma, accelerates gastric ulcer healing in rat. Eur J Pharmacol 2003; 472: 213-220.
• Konturek PC, Burnat G, Brzozowski T, Zopf Y, Konturek SJ. Tryptophan free diet delays healing of chronic gastric ulcers in rat. J Physiol Pharmacol 2008; 59(Suppl 2): 53-65.
• Brzozowski T, Konturek PC, Sliwowski Z, et al. Gastroprotective action of orexin-A against stress-induced gastric damage is mediated by endogenous prostaglandins, sensory afferent neuropeptides and nitric oxide. Regul Pept 2008; 148: 6-20.
• Ishibashi M, Egashira K, Hiasa K, et al. Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 2002; 40: 687-693.
• Tarnawski A. Cellular and molecular mechanisms of gastrointestinal ulcer healing. Dig Dis Sci 2005; 50(Suppl 1): S24-S33.
• Dudar GK, D'Andrea LD, Di Stasi R, Pedone C, Wallace JL. A vascular endothelial growth factor mimetic accelerates gastric ulcer healing in an iNOS-dependent manner. Am J Physiol Gastrointest Liver Physiol 2008; 295: G374-G381.
• Kawano S, Tsuji S. Role of mucosal blood flow: a conceptional review in gastric mucosal injury and protection. J Gastroenterol Hepatol 2000; 15(Suppl): D1-D6.
• Yasuda S, Kobayashi H, Iwasa M, et al. Antidiabetic drug pioglitazone protects the heart via activation of PPAR-gamma receptors, PI3-kinase, Akt, and eNOS pathway in a rabbit model of myocardial infarction. A J Physiol Heart Circ Physiol 2009; 296: H1558-H1565.
• Ohta Y, Kobayashi T, Inui K, Yoshino J, Nakazawa S. Repeated recurrence of gastric mucosal lesions in rats after a single treatment with compound 48/80, a mast cell degranulator. J Physiol Pharmacol 2009; 60(Suppl 7): 139-148.
• Moreno JM, Rodriguez Gomez I, Wangensteen R, et al. Mechanisms of hydrogen peroxide-induced vasoconstriction in the isolated perfused rat kidney. J Physiol Pharmacol 2010; 61: 325-332.
• Konturek PC, Sliwowski Z, Koziel J, et al. Probiotic bacteria Escherichia coli strain Nissle 1917 attenuates acute gastric lesions induced by stress. J Physiol Pharmacol 2009; 60(Suppl 6): 41-48.
• Choi SR, Lee SA, Kim YJ, Ok CY, Lee HJ, Hahm KB. Role of heat shock proteins in gastric inflammation and ulcer healing. J Physiol Pharmacol 2009; 60(Suppl 7): 5-17.
• Gawad A, Ptak-Belowska A, Brzozowski T, Pawlik WW. Monocytes and vascular endothelial cells apoptosis. Role of p-HSP27. J Physiol Pharmacol 2009; 60: 55-61.
• Filipovic D, Gavrilovic L, Dronjak S, Demajo M, Radojcic MB. Liver glucocorticoid receptor and heat shock protein 70 levels in rats exposed to different stress models. Physiol Res 2008; 57: 205-213.